Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

Also called NCT03029208

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03029208
  • EudraCT 2016-000507-86
Other papers using this trial's data
  • Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial JAMA internal medicine, 2022-06-01 DOI, PubMed 35377393, PMC8981070 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, Germany, India, Italy, Malaysia, Mexico, Poland, Russia, South Africa, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03029208. Randomized; no masking; primary purpose treatment. Start 2017-05-11 (actual); primary completion 2020-09-24 (actual). Results posted on 2021-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Condition
Anaemia
Intervention (Drug)
Daprodustat
Intervention (Drug)
Darbepoetin alfa
Intervention (Drug)
Iron therapy
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct03029208
Content hash
5e4773cf6c314f5f3ecf13cf3fcfca4370f07e416807fb4633ff755dd8a412f7